Trial reportCardiovascular diabetology2015
Differential response in levels of high-density lipoprotein cholesterol to one-year metformin treatment in prediabetic patients by race/ethnicity.
Trial report in Cardiovascular diabetology, 2015. The graph read 2 numbers from its abstract, feeding 1 cell of the map: it supports the treatment in 1. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
Interestingly, at year one in the placebo group, the levels of triglycerides, total cholesterol, VLDL and LDL-C were significantly reduced as well, with changes being -9.25 ± 73.84 (p <0.001), -4.04 ± 26.64 (p < 0.001), -1.70 ± 13.97 (p < 0.001) and -2.22 ± 24.67 (p = 0.006), respectively (Table 2).
Likewise, in the placebo group, both LDL B and C subfractions were decreased as well, with changes being -1.15 ± 13.51 (p < 0.001) and -2.65 ± 21.51 (p < 0.001), respectively.
clause the extractor read what became the number
Where it lands on the map
Rows are treatments, columns are outcomes. The coloured squares are the cells this paper feeds, coloured by the vote it casts there. Click one to jump to what this paper adds to it.
What it adds to each cell
For every cell the paper feeds: the belief in the claim with and without this paper, and this paper's estimate drawn against every other readable study in the cell. The ringed dot is this paper.
Metformin×lipids
SupportsOpen on the map →What to test next →10 readable studies in this cell: 4 favour the treatment, 5 find no difference, 1 favour the comparator.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Combined effect of metformin with ascorbic acid versus acetyl salicylic acid on diabetes-related cardiovascular complication; a 12-month single blind multicenter randomized control trial.Cardiovascular diabetology · 2017 · on this mapTrial
- Effects of the SGLT2 inhibitor dapagliflozin on HDL cholesterol, particle size, and cholesterol efflux capacity in patients with type 2 diabetes: a randomized placebo-controlled trial.Cardiovascular diabetology · 2017Trial
- Environmental Enrichment and Metformin Combination Improves Cognitive Function through BDNF and HPA Axis in Chronically Stressed Rats.Current Alzheimer research · 2025Article
- Examining the relationship between metformin dose and cancer survival: A SEER-Medicare analysis.PloS one · 2022Article
- Glycemic control is associated with dyslipidemia over time in youth with type 2 diabetes: The SEARCH for diabetes in youth study.Pediatric diabetes · 2021Article
- Racial differences in prevalence and severity of non-alcoholic fatty liver disease.World journal of hepatology · 2021Review
- Current Perspectives on the Beneficial Effects of Soybean Isoflavones and Their Metabolites for Humans.Antioxidants (Basel, Switzerland) · 2021Review
- Clinical relevance between sodium-glucose co-transporter 2 inhibitors and lipid profiles in Asian patients with type 2 diabetes mellitus: a systematic review with a meta-analysis of randomized controlled trials.Journal of pharmaceutical health care and sciences · 2020Article
- Actions of metformin and statins on lipid and glucose metabolism and possible benefit of combination therapy.Cardiovascular diabetology · 2018Review
- Racial Disparities in Obesity Treatment.Current obesity reports · 2018Review
- Current and future therapies for addressing the effects of inflammation on HDL cholesterol metabolism.British journal of pharmacology · 2017Review
- Common medications used by patients with type 2 diabetes mellitus: what are their effects on the lipid profile?Cardiovascular diabetology · 2016Review
- The improvement of large High-Density Lipoprotein (HDL) particle levels, and presumably HDL metabolism, depend on effects of low-carbohydrate diet and weight loss.EXCLI journal · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
The marked sentences are the ones the graph read a number from.
backgroundAs a first-line diabetes drug that is widely prescribed around the world, metformin has been demonstrated to be effective in reducing microvascular risk, in addition to lowering glucose levels. Specifically, metformin use has been shown to be associated with improved lipid profiles, such as increased levels of high-density lipoprotein cholesterol (HDL-C). However, no study has been performed to examine the differential response in HDL-C levels to metformin treatment by race/ethnicity.
methodsHere, based on a re-analysis of the data from the Diabetes Prevention Program, which involved pre-diabetic participants receiving 850 mg of metformin twice daily, we compared the lipid profile changes following the metformin use. The participants were composed of 602 Whites, 221 African Americans (AAs) and 162 Hispanics.
resultsWe found that the one-year metformin treatment resulted in a significant increase in HDL-C levels in Whites (p = 0.002) and AAs (p = 0.016), but not in Hispanics. Consistently, both Whites (p = 0.018) and AAs (p = 0.020) had more pronounced changes in HDL-C levels than Hispanics following metformin treatment.
conclusionThis result suggests a notion that Whites and AAs are more responsive than Hispanics to one-year metformin use in HDL-C level changes, and that racial and ethnic identity is a factor to consider when interpreting the effects of metformin treatment on lipid profiles.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.